Trends in Malignant Lacrimal Gland Tumors And Lacrimal Sac Tumors

Wei-Yu Lai, MD\textsuperscript{a}, Yaoh-shiang Lin, MD\textsuperscript{b}, Ching-Chih Lee, MD, PHD\textsuperscript{b,c}, Chun-Hao Yin\textsuperscript{c}

Email: Wei-Yu Lai \texttt{L.weiyuu@gmail.com}

Yaoh-shiang Lin

Yaohshiang@vghks.gov.tw

Ching-Chih Lee

enttcd16@gmail.com

Chun-Hao Yin Mo521141@gmail.com

\textsuperscript{a} Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung,

\textsuperscript{b} Department of Otolaryngology, Head and Neck Surgery,

Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

\textsuperscript{c} Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

*Correspondence to*: Chun-Hao Yin, Department of Medical Education and Research, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung 813, Taiwan, R.O.C.

Tel: +886 7 346 8217 Fax +886 7 346 8216,
Email: Mo521141@gmail.com
This study was supported by the Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. The authors have no proprietary or commercial interest in any of the materials discussed in this article.

Key words:
Lacrimal gland malignancy, Lacrimal sac malignancy, Incidence, Trends
Background: Malignant tumors of the lacrimal gland and lacrimal sac are rare entities, and their incidence has been decreasing. In this study, the incidence trend was examined in relation to patient demographics of these rare tumors.

Methods: In patient data obtained from the NCI Surveillance Epidemiology and End Results (SEER) database, International Classification of Diseases for Oncology, third edition (ICD-O-3) codes for lacrimal gland and lacrimal sac tumors (C69.5) were used to identify patients with the aforementioned malignancies. Demographic data, tumor size, treatment, and outcomes were analyzed. Tumor-node-metastasis (TNM) staging subgroup analysis was conducted for patients who had received AJCC 6th edition staging at diagnosis. The trend of the incidence rate was calculated per 100,000 person-years by using the joinpoint analysis and age adjusted to the 2000 US standard population (single ages-census P25-1130). All tests of statistical significance were two-tailed, and $p$-value of $<0.05$ were considered statistically significant.

Results: The trend of lacrimal gland malignancies has decreased significantly over the years in the white patients. Among the female patients, the incidence rate was significantly lower in female white patients than in the female nonwhite patients. The 5-year survival rate was relatively higher in the patients with lacrimal gland malignancies smaller than 2.5 cm ($p$-value = .007). The female patients with low socioeconomic status had significantly higher incidence rates ($p$-value = .041) of lacrimal sac malignancies than did those with high socioeconomic status.

Conclusions: Lacrimal gland and lacrimal sac malignancies have been decreasing overall in recent years in the USA. The trend of lacrimal gland malignancies has decreased significantly over the years in the white patients. Incidence rate vary in gender, race, and socioeconomic status in lacrimal gland and lacrimal sac malignancies. Analysis of lacrimal gland and
lacrimal sac malignancy trends improved our knowledge of predisposed populations as well as diagnoses.
1. Background

Malignant tumors of the lacrimal drainage system are rare,\textsuperscript{1-3} with an estimated annual incidence of 0.072 per 100,000 people.\textsuperscript{4} These tumors have been reported to be associated with high morbidity and mortality,\textsuperscript{3,5-9} and early treatment is crucial. However, diagnosis is often delayed because the symptoms, such as epiphora, a palpable mass, are often confused with those of a relatively benign etiology. Thus far, few studies have examined the incidence trends of lacrimal gland and lacrimal sac malignancies in the United States. In this study, the incidence and survival trends of patients with primary malignant tumors of the lacrimal gland and lacrimal sac were examined in a large population by using data from the population-based US National Cancer Institute’s SEER cancer registry.
2. Methods

A population-based cohort analysis of patients who had received a diagnosis of primary malignant tumors in the lacrimal gland and lacrimal sac was performed using the case-listing session of the SEER 18 database (www.seer.cancer.gov). The current SEER database, managed by the US National Cancer Institute, includes 17 cancer registries. It is an open-access resource for cancer-based epidemiology and survival analyses. The SEER*Stat software (seer.cancer.gov/seerstat), version 8.3.5, from the National Cancer Institute was used to identify patients who had received diagnoses of lacrimal gland and lacrimal sac malignancies between January 1, 2009, and December 31, 2015. Moreover, the annual percent change (APC) in rate was quantified using NCI’s Joinpoint Regression Program (version 4.6.0). Because data were extracted from a public, deidentified database, this study did not require an approval from an institutional review board.

The database is a widely used cancer registry that covers an estimated 28% of the US population, and African American and Hispanic individuals constitute 23% and 40% of the covered population. Geographic regions covered include San Francisco-
Oakland, Connecticut, metropolitan Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah, metropolitan Atlanta, San Jose–Monterey, Los Angeles, Alaska,
rural Georgia, California, Kentucky, Louisiana, New Jersey, and
Greater Georgia. Patients with a primary tumor of the lacrimal
gland and lacrimal sac from 2009 through 2015, the widest date
range available in the latest version of the SEER software, were
identified using the primary site label C69.5.

Next, we used site-specific data items (SSDIs) to discriminate
between the lacrimal sac and lacrimal gland. The following primary
data were extracted from the database for analysis: age at
diagnosis, sex, race, socioeconomic status, marital status, tumor
extent, and tumor size from both extent of disease and
collaborative stage coding methods, tumor grade, tumor TNM
stage, treatment methods, and 5-year survival in months. Well-
differentiated and moderately differentiated histological subtypes
were grouped as low-grade tumors, whereas poorly differentiated
and undifferentiated histological subtypes were grouped as high-
grade tumors. Lymphomas and melanomas were excluded.

The trend of the incidence rate examined using the joinpoint
analysis was calculated per 100,000 person-years and age adjusted
to the 2000 US standard population (single ages-census P25-1130);
confidence intervals were set as 95% for rates and trends.
Percentage changes were calculated using one year for each endpoint. APCs were calculated using the weighted least-squares method. APCs were calculated
on the basis of the entire study duration. Because data were extracted from a public, identified database, this study did not require approval from an institutional review board. Statistical analyses were performed using SPSS (version 20, SPSS Inc, Chicago, IL, USA). Because data was extracted from a public, deidentified database, this study did not require an institutional review board approval.
Results

Lacrimal gland malignancy

In total, 114 patients with lacrimal gland malignancies were included in the study. Table 1 summarizes baseline patient demographics. In the patient population, 55% and 45% were male and female patients, respectively, and 32% and 68% were white and nonwhite patients, respectively. The overall mean patient age at diagnosis was 56 ± 18 years. Radiation therapy was administered to 63% of the patients, and 87% of the patients underwent surgery. Chemotherapy was administered to 24% of the patients. Among the patients with malignancies with adequate tumor staging data, the staging of 32% and 53% of the tumors was I or II and III or IV, respectively. Among the patients with data of histological tumor grades, 27% had well- or moderately differentiated tumors and 26% had poorly or undifferentiated tumors. The trend line of lacrimal gland malignancies showed a significant decrease over the years in the white patients. The average APC (AAPC) was statistically significant (−11.8, p-value = .046) (Table 2).
The incidence rate was significantly lower in the white female patients than in the nonwhite female patients (0.013 vs 0.024, *p*-value = .023); however, no significant difference was observed between the white and nonwhite male patients (0.023 vs
0.029, \( p\text{-value} = .492 \)). No significant difference was observed in the lacrimal gland malignancy incidence rate when we stratified the population for analysis by sex and socioeconomic status. The 5-year survival rate in the patients with lacrimal gland malignancies was significantly higher in the subgroup p1 + p2 than in the subgroup p3 + p4 (91% vs 59%, \( p\text{-value} = .007 \)). Regarding the mortality trend, overall, a decreasing trend was observed in APC \((-4.5, \ p\text{-value} = 0.094\) (Table 3)

**Lacrimal sac malignancy**

In total, 49 patients with lacrimal sac malignancies were included in the study. Table 1 summarizes baseline patient demographics. The study population comprised 53% and 47% male and female patients, respectively, and 31% and 69% white and nonwhite patients, respectively. The overall mean patient age at diagnosis was 64 ± 16 years. Radiation therapy was administered to 65% of the patients, and 84% of the patients underwent surgery. Chemotherapy was administered to 14% of the patients. Among the patients with adequate tumor staging data, 14% and 65% of the malignancies were staged as I or II and III or IV, respectively. Among the patients with histological tumor grade data, 39% had
well- or moderately differentiated tumors and 27% were poorly
differentiated or undifferentiated tumors. A nonsignificant decrease
was observed in the incidence rate of lacrimal sac
malignancies. (table 4.) No
significant differences were noted in the survival rate and mortality in the subgroups after stratification by age, sex, and race (white or nonwhite). The female patients with low socioeconomic status had a significantly higher incidence rate than those with high socioeconomic status (0.004/100,000 vs 0.002/100,000, \( p\text{-value} = .041 \)), whereas no significant difference was observed in the male patients with different socioeconomic status.
Discussion

The overall incidence rate of lacrimal gland malignancies exhibited a significant decreasing trend from 2009 through 2015 in white patients. Among the female patients, the white patients had a significantly lower incidence rate than did the nonwhite patients. The patients with a lacrimal gland malignancy size of <2.5 cm had a significantly higher 5-year survival rate than did those with a tumor size of >2.5 cm. Regarding lacrimal sac malignancies, the female patients with low socioeconomic status exhibited a significantly higher incidence rate than did those with high socioeconomic status.

To our knowledge, our study is one of the few studies to describe the incidence trends of malignancies of the lacrimal gland and lacrimal sac in a large number of patients. SEER provides diverse validated databases with appropriate quality control. Besides, SEER database allows study of rare malignancies with great statistical power. We combined ICD codes and SSDIs to discriminate between malignancies of the lacrimal sac and lacrimal gland; however, other studies have overlooked differences in their
anatomical locations and have included both types of malignancies by using the same code C69.5.

Two studies analyzing the epidemiology of primary lacrimal gland malignancies
based on the population-based database of the US National Cancer Institute’s SEER Program have been published.\textsuperscript{5,10} Both the aforementioned studies identified that adenoid cystic carcinoma is the most common malignant epithelial neoplasm of the lacrimal gland.\textsuperscript{5,10} Age at diagnosis and surgical treatment are independent determinants of survival in patients with tumors of the lacrimal gland.\textsuperscript{5} Tumor histology differs in survival rate and among different sex.\textsuperscript{10,11} A Japanese survey on lacrimal gland cancer showed that the pathological diagnosis differed according to sex. According to the survey results, women had a higher rate of pleomorphic adenoma, whereas men had a higher rate of malignant epithelial tumor.\textsuperscript{11} The proportion of lacrimal gland cancer diagnosed as lymphoma has steadily increased over time\textsuperscript{1,10} and has been associated with more favorable survival rates. Currently, a study on lacrimal sac malignant tumors using the SEER database is not available. Ni et al. retrospectively studied 82 cases of lacrimal sac tumor in a single hospital. Their experience in China found malignant lacrimal sac not as rare as compared with literature and reported a high overall mortality (37.5%), high incidence of lymphatic metastasis (27%), and significant hematogenous metastasis (9.1%). Montalban et al conducted a 15-year
retrospective review of malignant lacrimal sac tumor and found a high recurrence rate (29%). Parmar and Rose also conducted a retrospective review and found 40% recurrence. High tumor staging and large size have been associated
with an increase in metastatic risk and low survival rates.\textsuperscript{13,14}

One limitation of this study is the lack of laboratory data, timing, and duration of intervention. Furthermore, the SEER database does not cover the entire population. However, SEER provides demographic characteristics that adequately represent the entire US population. In future studies, we expect to use the National Health Insurance Research Database of Taiwan, which covers 99.9\% of the population of Taiwan and provides multicenter data, specific treatment protocols, and treatment duration.

The current study offers longitudinal data on a vast, diverse population of malignant lacrimal gland and lacrimal sac tumors. This epidemiological data regarding patient demographics improves our knowledge of predisposed populations for these diagnoses.
Conclusions

Lacrimal gland and lacrimal sac malignancies have been decreasing overall in recent years in the USA. Our study revealed that the incidence of the aforementioned malignancies vary with sex, race, and socioeconomic status. The trend of lacrimal gland malignancies has decreased significantly over the years in the white patients. This analysis of lacrimal gland and lacrimal sac malignancy trend improves our knowledge of predisposed populations during diagnosis.
Declarations

Abbreviations
Not applicable

Ethics approval and consent to participate
Because data was extracted from a public, deidentified database, this study did not require an institutional review board approval.

Competing Interests
The authors declare no Competing Interests.

Consent form
Not applicable

Availability of data and material
A population-based cohort analysis of patients who had received a diagnosis of primary malignant tumors in the lacrimal gland and lacrimal sac was performed using the case-listing session of the SEER 18 database (www.seer.cancer.gov).

Funding
Not applicable

Authors' contributions
‘WY Lai’ and ‘CH Yin’ conceived of the presented idea. ‘WY Lai’ and ‘CH Yin’ developed the theory and performed the computations. ‘CC Lee’ and ‘YS Lin’ verified the analytical methods. ‘CC Lee’ encouraged ‘WY Lai’ to investigate and supervised
the findings of this work. All authors discussed the results and contributed to the final manuscript.

**Acknowledgement**

The authors express their appreciation to the Department of Medical Education and Research Center of Medical Informatics in Kaohsiung Veterans General Hospital for inquiries and assistance in data processing (grant no. VGHKS-D12-1).
Reference

1. Hassan WM, Bakry MS, Hassan HM, Alfaar AS. Incidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from Surveillance, Epidemiology and End Results, 1973-2009. *Int J Ophthalmol.* 2016;9(12):1808-1813.

2. Skinner HD, Garden AS, Rosenthal DI, et al. Outcomes of malignant tumors of the lacrimal apparatus: the University of Texas MD Anderson Cancer Center experience. *Cancer.* 2011;117(12):2801-2810.

3. Heindl LM, Junemann AG, Kruse FE, Holbach LM. Tumors of the lacrimal drainage system. *Orbit (Amsterdam, Netherlands).* 2010;29(5):298-306.

4. von Holstein SL, Therkildsen MH, Prause JU, Stenman G, Siersma VD, Heegaard S. Lacrimal gland lesions in Denmark between 1974 and 2007. *Acta ophthalmologica.* 2013;91(4):349-354.

5. Mallen-St Clair J, Arshi A, Tajudeen B, Abemayor E, St John M. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. *JAMA Otolaryngol Head Neck Surg.* 2014;140(12):1110-1116.

6. Montalban A, Lietin B, Louvrier C, et al. Malignant lacrimal sac tumors. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2010;127(5):165-172.

7. Ni C, D'Amico DJ, Fan CQ, Kuo PK. Tumors of the lacrimal sac: a clinicopathological analysis of 82 cases. *International ophthalmology clinics.* 1982;22(1):121-140.

8. Woo KI, Kim YD, Sa HS, Esmaeli B. Current treatment of lacrimal gland carcinoma. *Curr Opin Ophthalmol.* 2016;27(5):449-456.

9. Woo KI, Yeom A, Esmaeli B. Management of Lacrimal Gland Carcinoma: Lessons From the Literature in the Past 40 Years. *Ophthalmic Plast Reconstr Surg.* 2016;32(1):1-10.

10. Andreoli MT, Aakalu V, Setabutr P. Epidemiological trends in malignant lacrimal gland tumors. *Otolaryngol Head Neck Surg.* 2015;152(2):279-283.

11. Group LGTS. An epidemiological survey of lacrimal fossa lesions in Japan: number of patients and their sex ratio by pathological diagnosis. *Jpn J*
12. Parmar DN, Rose GE. Management of lacrimal sac tumours. *Eye (London, England)*. 2003;17(5):599-606.

13. Krishna Y, Coupland SE. Lacrimal Sac Tumors--A Review. *Asia Pac J Ophthalmol (Phila)*. 2017;6(2):173-178.
14. Low JR, Bian Ng S, Sundar G. Undifferentiated carcinoma of the lacrimal sac: case report and review of literature. *Orbit (Amsterdam, Netherlands)*. 2011;30(6):293-296.